Recently, it has been shown that targeting SWI/SNF activity blocks the enhancer-binding activity of transcription factors involved in prostate cancer progression, and results in a remarkable reduction in tumor growth in a mouse model of CRPC (85). Here, SMARCA1 is linked to prostate carcinoma.